Vaccination with Phosphoglycan-Deficient Leishmania major Protects Highly Susceptible Mice from Virulent Challenge without Inducing a Strong Th1 Response

Journal of Immunology

Volumn 172, Issue 6, 2004, Pages 3793-3797

  Uzonna, Jude E ^a   Späth, Gerald F ^b,c   Beverley, Stephen M ^b   Scott, Phillip ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LIPOPHOSPHOGLYCAN; PARASITE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOSTIMULATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; MOUSE STRAIN; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; TH1 CELL; VACCINATION;

EID: 1542619246     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.6.3793     Document Type: Article

References (32)

1. Desjeux, P. 1992. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q. 45:267.
2. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl.)1:83.
3. Satti, I. N., H. Y. Osman, N. S. Daifalla, S. A. Younis, E. A. Khalil, E. E. Zijlstra, A. M. El Hassan, and H. W. Ghalib. 2001. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 19:2100.
4. Modabber, F. 1990. Development of vaccines against leishmaniasis. Scand. J. Infect. Dis. Suppl. 76:72.
5. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845.
6. Uzonna, J. E., G. Wei, D. Yurkowski, and P, Bretscher. 2001. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167:6967.
7. + regulatory T cells control Leishmania major persistence and immunity. Nature 420:502.
8. Mitchell, G. F., E. Handman, and T. W. Spithill. 1984. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust. J. Exp. Biol. Med. Sci. 62:145.
9. Mitchell, G. F., and E. Handman. 1983. Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility. Aust. J. Exp. Biol. Med. Sci. 61:11.
10. Spath, G. F., L. Epstein, B. Leader, S. M. Singer, H. A. Avila, S. J. Turco, and S. M. Beverley. 2000. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc. Natl. Acad. Sci. USA 97:9258.
11. Titus, R. G., F. J. Gueiros-Filho, L. A. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92:10267.
12. Alexander, J., G. H. Coombs, and J. C. Mottram. 1998. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161:6794.
13. Cruz, A., C. M. Coburn, and S. M. Beverley. 1991. Double targeted gene replacement for creating null mutants. Proc. Natl. Acad. Sci. USA 88:7170.
14. Cruz, A., and S. M. Beverley. 1990. Gene replacement in parasitic protozoa. Nature 348:171.
15. Huang, C., and S. J. Turco. 1993. Defective galactofuranose addition in lipophosphoglycan biosynthesis in a mutant of Leishmania donovani. J. BioL Chem. 268:24060.
16. Ryan, K. A., L. A. Garraway, A. Descoteaux, S. J. Turco, and S. M. Beverley. 1993. Isolation of virulence genes directing surface glycosyl-phosphatidylinositol synthesis by functional complementation of Leishmania, Proc. Natl. Acad. Sci. USA 90:8609.
17. Spath, G. F., L. F. Lye, H. Segawa, D. L. Sacks, S. J. Turco, and S. M. Beverley. 2003. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301:1241.
18. Ma, D., D. G. Russell, S. M. Beverley, and S. J. Turco. 1997. Golgi GDP-mannose uptake requires Leishmania LPG2: a member of a eukaryotic family of putative nucleotide-sugar transporters. J. Biol. Chem. 272:3799.
19. Descoteaux, A., Y. Luo, S. J. Turco, and S. M. Beverley. 1995. A specialized pathway affecting virulence glycoconjugates of Leishmania. Science 269:1869.
20. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545.
21. Park, A. Y., B. D. Hondowicz, and P. Scott. 2000. IL-12 is required to maintain a Th1 response during Leishmania major infection. J. Immunol. 165:896.
22. Veras, P., C. Brodskyn, F. Balestieri, F. Ld, A. Ramos, A. Queiroz, A. Barral, S. Beverley, and M. Barral-Netto. 1999. A dhfr-ts-Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem. Inst. Oswaldo Cruz 94:491.
23. Amaral, V. F., A. Teva, M. P. Oliveira-Neto, A. J. Silva, M. S. Pereira, E. Cupolillo, R. Porrozzi, S. G. Coutinho, C. Pirmez, S. M. Beverley, and G. Grimaldi, Jr. 2002. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem. Inst. Oswaldo Cruz 97:1041.
24. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature 401:708.
25. Sprent, J., and C. D. Surh, 2002. T cell memory. Annu. Rev. Immunol. 20:551.
26. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225.
27. + effector and memory T cell generation. Nat. Immunol. 4:835.
28. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. Establishment of stable, cell-mediated immunity that makes " susceptible" mice resistant to Leishmania major. Science 257:539.
29. Menon, J. N., and P. A. Bretscher. 1996. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur. J. Immunol. 26:243.
30. Piedrafita, D., L. Proudfoot, A. V. Nikolaev, D. Xu, W. Sands, G. J. Feng, E. Thomas, J. Brewer, M. A. Ferguson, J. Alexander, and F. Y. Liew. 1999. Regulation of macrophage IL-12 synthesis by Leishmania phosphoglycans. Eur. J. Immunol. 29:235.
31. Gicheru, M. M., J. O. Olobo, C. O. Anjili, A. S. Orago, F. Modabber, and P. Scott. 2001. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69:245.
32. Ilg, T., M. Demar, and D. Harbecke. 2001. Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. J. Biol. Chem. 276:4988.